Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2021 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces New Global Chief Business Officer and Expansion of US Corporate Activities

CBO joins from AIG Asset ManagementTo lead global business strategy and US corporate initiatives from US base MADRID, Spain and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
November 17, 2021 13:20 ET | Source: Entreprises Minières Globex Inc.

Globex fait l’acquisition d’un imposant terrain uranifère

ROUYN-NORANDA, Québec, 17 nov. 2021 (GLOBE NEWSWIRE) -- ENTREPRISES MINIÈRES GLOBEX INC. (GMX – Bourse de Toronto, G1MN – Bourses de Francfort, Stuttgart, Berlin, Munich, Tradegate, Lang &...
November 17, 2021 13:20 ET | Source: Globex Mining Enterprises Inc.

Globex Acquires Large Uranium Land Package

ROUYN-NORANDA, Quebec, Nov. 17, 2021 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS...
November 17, 2021 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Enrolls First Patient in EVOLUTION, a Phase IIb Clinical Trial With Vafidemstat in Schizophrenia

Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophreniaPhase IIb adaptive trial planning to enroll 100 patientsSecond Phase IIb study of...
November 16, 2021 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea gibt Einreichung eines Investigational New Drug-Antrags für Medikamentenkandidaten BAL0891 zur Krebsbehandlung bekannt

Potenzial für Erweiterung der Onkologie-Pipeline um drittes klinisches ProgrammFortschritte bei Patientenrekrutierung in Richtung Interim-Analysen für Phase-2-Studie mit Lisavanbulin sowie bei...
November 16, 2021 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891

Potential to add third clinical-stage program to oncology pipelineProgressing patient enrolment towards interim analyses in lisavanbulin phase 2 study and in patient cohorts in FIDES-01 and FIDES-02...
November 15, 2021 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Publishes Paper in ACS Pharmacology & Translational Science Supporting Best-in-Class Performance of Iadademstat in Oncology

Iadademstat consistently stronger in viability reduction in AML & SCLC cellsSuperior target engagement at low concentration in AML & SCLC cells Superior disruption of the Snag-domain...
November 09, 2021 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in November and December

Jefferies London Healthcare Conference 2021Evercore ISI 4th Annual HealthCONx Conference 202163th American Society of Hematology 2021 Congress (ASH-2021) MADRID, Spain and CAMBRIDGE, Mass., Nov. 09,...
October 29, 2021 01:30 ET | Source: Compagnie Financière Tradition

Compagnie Financière Tradition: Growth in adjusted revenue by 6.6% in the 3rd quarter to CHF 220.5m

Ad hoc announcement pursuant to Article 53 of the Six Exchange Regulation Listing Rules Lausanne, 29 October 2021 Growth in adjusted revenue by 6.6% in the 3rd quarter to CHF 220.5m ...
October 29, 2021 01:30 ET | Source: Compagnie Financière Tradition

Compagnie Financière Tradition: Growth in adjusted revenue by 6.6% in the 3rd quarter to CHF 220.5m

Ad hoc announcement pursuant to Article 53 of the Six ExchangeRegulation Listing Rules Lausanne, 29 October 2021 Growth in adjusted revenue by 6.6% in the 3rd quarter to CHF 220.5m ...